



PATENT  
Docket No.: 2809/1371

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Beck et al.

Serial No. : 09/704,306

Cnfrm. No. : 4919

Filed : November 2, 2000

For : NOVEL 4-PHENYL SUBSTITUTED  
TETRAHYDROISOQUINOLINES AND USE  
THEREOF

)  
) Examiner:  
) Brenda L. Coleman

)  
) Art Unit:  
) 1624

INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR §§ 1.97-1.98

**Mail Stop RCE**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR §§ 1.97-1.98, applicants hereby bring to the attention of the United States Patent and Trademark Office, the enclosed references listed on the attached PTO/SB/08 form.

Pursuant to 37 C.F.R. § 1.98(a)(2)(ii), copies of the cited U.S. Patents (i.e., Reference Cite Nos. 1-3) are not enclosed. Copies of all other listed references (i.e., Reference Cite Nos. 4-10) are enclosed herewith.

Respectfully submitted,

Date: June 6, 2006

Alice Y. Choi


Alice Y. Choi  
Registration No. 45,758

NIXON PEABODY LLP  
Clinton Square, P.O. Box 31051  
Rochester, New York 14603-1051  
Telephone: (585) 263-1508  
Facsimile: (585) 263-1600

**Certificate of Mailing - 37 CFR 1.8(a)**

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to:  
Commissioner for Patents P.O. Box 1450  
Alexandria, VA 22313-1450, on the date below

June 6, 2006 Ruth R. Smith  
Date Ruth R. Smith



Substitute for form 1449A/PTO			Complete if Known		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary) Sheet 1 of 1			Application Number	09/704,306	
			Filing Date	November 2, 2000	
			First Named Inventor	James P. Beck	
			Art Unit	1624	
			Examiner Name	Brenda L. Coleman	
			Attorney Docket Number	2809/1371	
<b>U.S. PATENT DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	US-4,564,613	01-14-1986	Boltze et al.	
	2	US-6,579,885	06-17-2003	Beck et al.	
	3	US-6,911,453	06-28-2005	Hofmeister et al.	
<b>FOREIGN PATENT DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear T <sup>6</sup>
	4	WO 02/04455 A2	01-17-2002	Beck et al.	
	5	EP 0 140 070 A1	05-08-1985	Boltze et al.	(English abstract)
<b>OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. T <sup>2</sup>			
	6	BURROWS et al., "Antidepressant Efficacy and Tolerability of the Selective Norepinephrine Reuptake Inhibitor Reboxetine: A Review," <i>J. Clin. Psychiatry</i> 59 (Suppl. 14):4-7 (1998) (98819-76-2 REGISTRY (Reboxetine))			
	7	DESAI et al., "Relationship Between in Vivo Occupancy at the Dopamine Transporter and Behavioral Effects of Cocaine, GBR 12909 [1-{2-[Bis-(4-fluorophenyl)methoxy]ethyl}-4-(3-phenylpropyl)piperazine], and Benztropine Analogs," <i>JPET</i> 315(1):397-404 (2005)			
	8	HYTTEL, "Pharmacological Characterization of Selective Serotonin Reuptake Inhibitors (SSRIs)," <i>Int. Clin. Psychopharmacol.</i> 9(Suppl. 1):19-26 (1994) (61869-08-7 REGISTRY (Paroxetine); 59729-32-7 REGISTRY (Citalopram); 79559-97-0 REGISTRY (Sertraline); 54910-89-3 REGISTRY (Fluoxetine); 54739-18-3 REGISTRY (Fluvoxamine))			
	9	KAMETANI et al., "Studies on the Synthesis of Heterocyclic Compounds-DXCI," <i>Tetrahedron</i> 31:235-238 (1975)			
	10	MÜLLER, "Current St. John's Wort Research from Mode of Action to Clinical Efficacy," <i>Pharmacological Research</i> 47:101-109 (2003)			
Examiner Signature	Date Considered				

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.



Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	09/704,306
Filing Date	November 2, 2000
First Named Inventor	James P. Beck
Art Unit	1624
Examiner Name	Brenda L. Coleman
Attorney Docket Number	2809/1371

Sheet

1

of

1

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document Number - Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	US-4,564,613	01-14-1986	Boltze et al.	
	2	US-6,579,885	06-17-2003	Beck et al.	
	3	US-6,911,453	06-28-2005	Hofmeister et al.	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	4	WO 02/04455 A2	01-17-2002	Beck et al.		
	5	EP 0 140 070 A1	05-08-1985	Boltze et al.		(English abstract)

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	6	BURROWS et al., "Antidepressant Efficacy and Tolerability of the Selective Norepinephrine Reuptake Inhibitor Reboxetine: A Review," <i>J. Clin. Psychiatry</i> 59 (Suppl. 14):4-7 (1998) (98819-76-2 REGISTRY (Reboxetine))	
	7	DESAI et al., "Relationship Between in Vivo Occupancy at the Dopamine Transporter and Behavioral Effects of Cocaine, GBR 12909 [1-{2-[Bis-(4-fluorophenyl)methoxy]ethyl}-4-(3-phenylpropyl)piperazine], and Benztropine Analogs," <i>JPET</i> 315(1):397-404 (2005)	
	8	HYTTEL, "Pharmacological Characterization of Selective Serotonin Reuptake Inhibitors (SSRIs)," <i>Int. Clin. Psychopharmacol.</i> 9(Suppl. 1):19-26 (1994) (61869-08-7 REGISTRY (Paroxetine); 59729-32-7 REGISTRY (Citalopram); 79559-97-0 REGISTRY (Sertraline); 54910-89-3 REGISTRY (Fluoxetine); 54739-18-3 REGISTRY (Fluvoxamine))	
	9	KAMETANI et al., "Studies on the Synthesis of Heterocyclic Compounds-DXCI," <i>Tetrahedron</i> 31:235-238 (1975)	
	10	MÜLLER, "Current St. John's Wort Research from Mode of Action to Clinical Efficacy," <i>Pharmacological Research</i> 47:101-109 (2003)	

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, Washington, DC 20231.